Classification of patients with relapsed/refractory large B-cell lymphoma who do not develop early CRS/NE toxicity using ZUMA clinical trial data.

Journal: Journal for immunotherapy of cancer
Published Date:

Abstract

BACKGROUND: We aimed to develop an actionable and feasible prospective clinical model to estimate toxicity risk to assist chimeric antigen receptor (CAR) T-cell therapy providers with the management of patients with relapsed and/or refractory large B-cell lymphoma.

Authors

  • Kelly Speth
    Kite, a Gilead Company, Santa Monica, California, USA.
  • Jin Xie
    School of Mathematics and Statistics, Xidian University, Xi'an 710071, PR China. Electronic address: xj6417@126.com.
  • Qinghua Song
    Key Laboratory of High Efficiency and Clean Mechanical Manufacture, Ministry of Education, School of Mechanical Engineering, Shandong University, Jinan 250061, China.
  • Mike Mattie
    Kite, a Gilead Company, Santa Monica, California, USA.
  • Jenny J Kim
    Kite, a Gilead Company, Santa Monica, California, USA.
  • David M Barrett
    Kite, a Gilead Company, Santa Monica, California, USA.
  • Jorge Andrade
    Kite, a Gilead Company, Santa Monica, California, USA.
  • Rhine Shen
    Kite, a Gilead Company, Santa Monica, California, USA.
  • Davide Bedognetti
    Kite, a Gilead Company, Santa Monica, California, USA sadhikary@kitepharma.com dbedognetti@kitepharma.com.
  • Sabina Adhikary
    Kite, a Gilead Company, Santa Monica, California, USA sadhikary@kitepharma.com dbedognetti@kitepharma.com.